Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $20.14

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has earned a consensus rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $20.14.

Several equities research analysts have recently issued reports on ACRV shares. JMP Securities reissued a “market outperform” rating and issued a $14.00 price objective on shares of Acrivon Therapeutics in a research report on Monday, April 1st. LADENBURG THALM/SH SH cut their price objective on Acrivon Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, April 5th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Acrivon Therapeutics in a research report on Monday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Acrivon Therapeutics in a research note on Thursday, March 28th.

Insider Transactions at Acrivon Therapeutics

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc purchased 2,353,000 shares of Acrivon Therapeutics stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average price of $8.50 per share, with a total value of $20,000,500.00. Following the completion of the acquisition, the insider now owns 5,360,858 shares of the company’s stock, valued at approximately $45,567,293. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

A hedge fund recently raised its stake in Acrivon Therapeutics stock. Exchange Traded Concepts LLC boosted its stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 34.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,289 shares of the company’s stock after acquiring an additional 3,370 shares during the period. Exchange Traded Concepts LLC owned 0.06% of Acrivon Therapeutics worth $65,000 at the end of the most recent reporting period. 71.62% of the stock is currently owned by hedge funds and other institutional investors.

Acrivon Therapeutics Trading Up 1.3 %

Shares of Acrivon Therapeutics stock opened at $9.51 on Friday. The business’s fifty day moving average price is $6.22 and its 200 day moving average price is $5.29. Acrivon Therapeutics has a twelve month low of $3.19 and a twelve month high of $14.30. The stock has a market capitalization of $215.31 million, a P/E ratio of -3.48 and a beta of 1.93.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its earnings results on Thursday, March 28th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). As a group, sell-side analysts predict that Acrivon Therapeutics will post -3.42 EPS for the current year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.